Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

被引:89
作者
Mohty, M
Jacot, W
Faucher, C
Bay, JO
Zandotti, C
Collet, L
Choufi, B
Bilger, K
Tournilhac, O
Vey, N
Stoppa, AM
Coso, D
Gastaut, JA
Viens, P
Maraninchi, D
Olive, D
Blaise, D
机构
[1] Inst J Paoli I Calmettes, Unite Transplantat & Therapie Cellulaire, F-13273 Marseille 09, France
[2] Univ Mediterranee, Marseille, France
[3] Inst J Paoli I Calmettes, Lab Immunol Tumeurs, F-13009 Marseille, France
[4] Ctr Jean Perrin, Unite Transplantat Medullaire, Clermont Ferrand, France
[5] Univ Marseille, Marseille, France
[6] Hop Enfants La Timone, Virol Lab, Ctr Hosp, Marseille, France
[7] Inst J Paoli I Calmettes, Dept Microbiol, F-13009 Marseille, France
[8] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[9] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
关键词
infections; allogeneic stem cell transplantation; reduced-intensity conditioning;
D O I
10.1038/sj.leu.2403105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the setting of reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT), the epidemiology of transplant-related infections is still poorly defined. In 101 high-risk patients who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan and antithymocyte globulin (ATG), we report during the first 6 months a cumulative incidence of positive CMV antigenemia of 42% (95% CI 32-52%), developing at a median of 37 (range 7-116) days without evidence of CMV disease (median follow-up, 434 days). The cumulative incidence of bacteremia was 25% (95% CI 17-33%), occurring at a median of 67 (range 7-172) days, while patients had recovered a full neutrophil count. In all, 65% of the bacteremia (95% CI 49-81%) were gram negative. The cumulative incidence of fungal infections was 8% (95% CI 3-13%), with a median onset of 89 (range 7-170) days. In multivariate analysis, stem cell source (bone marrow; P = 0.0002) was significantly associated with the risk of positive CMV antigenemia, while higher doses of prednisone (> 2 mg/kg) represented the major risk factor for bacteremia (P = 0.0001). Infectious-related mortality was 5% (95% CI 1-9%), with aspergillosis being the principal cause. Collectively, these results suggest that prospective efforts are warranted to develop optimal antimicrobial preventive strategies after RIC allo-SCT.
引用
收藏
页码:2168 / 2177
页数:10
相关论文
共 59 条
  • [11] Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    Childs, R
    Chernoff, A
    Contentin, N
    Bahceci, E
    Schrump, D
    Leitman, S
    Read, EJ
    Tisdale, J
    Dunbar, C
    Linehan, WM
    Young, NS
    Barrett, AJ
    Clave, E
    Epperson, D
    Mayo, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) : 750 - 758
  • [12] COX DR, 1972, J R STAT SOC B, V34, P187
  • [13] Early gram-positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis
    da Cunha, CA
    Weisdorf, D
    Shu, XO
    DeFor, T
    Pastor, JD
    Johnson, JR
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (02) : 173 - 180
  • [14] DEEG HJ, 1990, BONE MARROW TRANSPL, V6, P1
  • [15] EINSELE H, 1993, BLOOD, V82, P1672
  • [16] Early infection in bone marrow transplantation: Quantitative study of clinical factors that affect risk
    Engels, EA
    Ellis, CA
    Supran, SE
    Schmid, CH
    Barza, M
    Schenkein, DP
    Koc, Y
    Miller, KB
    Wong, JB
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) : 256 - 266
  • [17] Farmer E R, 1986, Adv Dermatol, V1, P173
  • [18] Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    Fukuda, T
    Boeckh, M
    Carter, RA
    Sandmaier, BM
    Maris, MB
    Maloney, DG
    Martin, PJ
    Storb, RF
    Marr, KA
    [J]. BLOOD, 2003, 102 (03) : 827 - 833
  • [19] Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
    Giralt, S
    Estey, E
    Albitar, M
    vanBesien, K
    Rondon, G
    Anderlini, P
    OBrien, S
    Khouri, I
    Gajewski, J
    Mehra, R
    Claxton, D
    Andersson, B
    Beran, M
    Przepiorka, D
    Koller, C
    Kornblau, S
    Korbling, M
    Keating, M
    Kantarjian, H
    Champlin, R
    [J]. BLOOD, 1997, 89 (12) : 4531 - 4536
  • [20] Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    Giralt, S
    Thall, PF
    Khouri, I
    Wang, XM
    Braunschweig, I
    Ippolitti, C
    Claxton, D
    Donato, M
    Bruton, J
    Cohen, A
    Davis, M
    Andersson, BS
    Anderlini, P
    Gajewski, J
    Kornblau, S
    Andreeff, M
    Przepiorka, D
    Ueno, NT
    Molldrem, J
    Champlin, R
    [J]. BLOOD, 2001, 97 (03) : 631 - 637